THE TAPE
OHI · REITs · $14.3B

Omega Healthcare Investors Inc.

$47.08▲ +0.06%
Last close
Relative strength
47RS
of 99, against every stock▲ +1 on the month
Turning up
Turning
−0.1%
six months against REITs
52-week range
−10.1%
from the high
$42.18$52.39
Setup
blue skyplayed out
−4.5%
against the pivot at $49.33
No report date on the calendar.
Growth FLATProof SHOWN
Quarter to Sep 30, revenue +9% on a year ago
11/16 O 47.37 H 47.54 L 46.85 Vol 2.1M
Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year

The four are not in order. That is a description of where the averages sit, not a view about what happens next.

RS47
vs pivot−4.55%
Tightening0.96×
Dry-up1.07×
Up/down vol0.03
From high10%
failed pokeplayed out6 of 9checks
Previous breakout trailed out ▼ −4.25% in Feb
Turning up
Support and resistance
Support below
$46.35
-1.6% · tested 5× · last 22 sessions ago
Resistance above
$48.08
+2.1% · tested 3× · last 45 sessions ago

Prices this stock has turned at three or more times in the last 120 sessions, with how many times. Where buyers and sellers showed up before, not a forecast, an entry or a stop.

The read

The base has run 5.8 weeks and fell 13% from its ceiling at its deepest. The pivot is $49.33, and the stock closed 4.5% below it. Its relative strength rating is 47.

Against its industry
TurningBehind its industry over six months, but ahead over one and three.
One month against its industry
+0.1%
Three months against its industry
+7.2%
Six months against its industry
-0.1%

Read against an equal-weighted index of REITs, which is -2.6% against the S&P 500 over six months Not aligned.

Also on
Peers
Same theme
No themes — common and fine.
Catalyst roadmap

Nothing dated in the next three months that we can ingest automatically.

How it moves on earnings

On average 3.6% either way across its last 8 reports.

Checking your subscription…

Close before the report day to close after it, so it holds whether the company reported before the open or after the close.

The business
Revenue
$1.3B
+9.3% year on year
Operating margin
—
Net margin
13.1%
Free cash flow
$854.9M
6.0% of market cap
Price to sales
10.9×
Price to earnings
82.8×

Twelve months to Sep 30, 2026, the four latest quarters in the company’s SEC filings, with the fiscal fourth quarter worked out from the annual report. Revenue growth is the latest quarter against the same quarter a year earlier.

The latest quarter, read by fixed rules · reported Nov 3
Key takeaway
Profitable and cash generating; the question is growth.
Revenue
$340.6M
+3.7% QoQ · +9.3% YoY
Gross margin
—
Net income
$83.1M
Positive
Free cash flow
$191.0M
Cash generating

What the numbers say

  • Revenue +9.3% year over year, +3.7% on the quarter
  • Good: Profitable: net income $83M, operating margin 97.4%
  • Good: Cash generating: operating cash flow $191M, free cash flow $191M
  • Good: Net cash $196M · cash $196M
Revenue by quarter
Free cash flow
Net income
shares +4.2% in a year · net cash $195.9M
Final read
Growth: FLAT · Economic proof: SHOWN
Key question: Can the cash generation hold as growth slows?
The next test is whether the quarter repeats.

From the company’s 10-Q and 10-K filings, by Market Desk’s rules. Every line, the takeaway and the final read are fixed rules on the filed numbers; nothing reads the press release, and none of it enters a screen or a rating. Every recent reporter.

Tracked funds

Held by 1 of 46 tracked funds at the end of Q3 2026.

Last quarter: 1 added, 1 sold out.

Checking your subscription…

From 13F filings, which show long stock only and arrive up to 45 days after the quarter. The broad quant funds are left out.

Flagged by the market sweep
Reported resultsFiling · 2026-11-04
2.02
No measurable effect: stocks behave like random ones over the next three sessions (2,340 cases over 54 nights).
Closed above its 20- and 50-day on heavy volumeTape · 2026-11-04
above 20d & 50d on 1.7x volume at 47.53
Mixed: stocks have outrun random stocks by 0.2% over three sessions, not consistently enough to call (1,668 cases over 60 nights). Against their own sector they have lagged by 0.7%.
A director or officer changedFiling · 2026-10-02
5.02
No measurable effect: stocks behave like random ones over the next three sessions (1,288 cases over 54 nights).
Unusual volumeTape · 2026-09-19
5.7 sigma
After this signal, stocks have lagged random stocks by 0.1% over the next three sessions (6,474 cases over 55 nights). Against their own sector they have lagged by 0.4%.

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.

In the news
Insiders

Nobody bought or sold on the open market in the last 6 months. There were 8 filings for awards, option exercises or shares withheld to pay tax — those happen on a vesting schedule, so they are not a decision to buy or sell.

Most recent filings
2026-10-01 Golem Lucas M. · CHIEF ACCOUNTING OFFICERaward64$2,520
2026-10-01 Golem Lucas M. · CHIEF ACCOUNTING OFFICERdisposition to issuer3$139
2026-08-07 Egbuonu-Davis Lisa · Directorgift5,131
2026-07-01 Ballew Neal · CHIEF ACCOUNTING OFFICERaward168$6,258
2026-07-01 Ballew Neal · CHIEF ACCOUNTING OFFICERdisposition to issuer11$524
2026-06-05 WHITMAN BURKE W · Directoraward3,778$164,985
2026-06-05 Jacobs Kevin J · Directoraward6,125$267,479
2026-06-05 Egbuonu-Davis Lisa · Directoraward3,778$164,985

From SEC Form 4, filed within two business days of the trade. What was filed, not what it means.

What lines up

6 of 9 published checks currently line up. This is a count, not a probability — nothing on this site measures how often a setup works.

Relative strength of 80 or better
Above its 50-day line
Above its 200-day line
Averages fully stacked
Within 5% of its pivot
Range tightening through the base
Volume drying up through the base
More up-volume than down-volume
Within 15% of its 52-week high
What analysts expect
Strong buy3
Buy6
Hold9
Sell0
Strong sell2

These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.

Checking your subscription…

Gamma concentration

No option open interest for this company. Most listed names have no options at all, and we only read chains for names carrying a dated event, so this is a normal reading rather than a fault.

X-ray
6w · 13%

The most recent of 3 completed bases.

Checking your subscription…

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. A stock on a screen matches a shape; that is not a prediction. Prices are end-of-day, not live.

What that means, in full
Omega Healthcare Investors Inc. (OHI) — The Tape